MAZE insider files to sell 74,853 shares

MAZE files a Form 144 to sell 74,853 shares of Common Stock via exercise of stock options on 03/10/2026.

Rhea-AI Filing Summary

MAZE files a Form 144 to sell 74,853 shares of Common Stock via exercise of stock options on 03/10/2026. The filing lists prior 10b5-1 dispositions by Harold Bernstein, including sales of 45,000 shares on 12/29/2025 and 25,156 shares on 01/07/2026

The notice states the method as cash proceeds from the option exercise; timing and final cash‑flow details follow the exercise on 03/10/2026.

Insights

Corporate Governance Analyst

Form 144 notifies a planned sale of 74,853 shares by an affiliate via option exercise.

The filing records an intended disposition of 74,853 Common shares on 03/10/2026 through exercise of stock options for cash. It also lists multiple prior 10b5-1 sales by Harold Bernstein, with notable amounts of 45,000 and 25,156 shares on 12/29/2025 and 01/07/2026.

These entries are routine compliance notices that disclose planned insider sales; cash‑flow treatment is described as cash from exercise. Subsequent filings will show actual proceeds and any post‑transaction holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does MAZE's Form 144 filing report?

The filing reports a proposed sale of 74,853 Common shares by exercise of stock options on 03/10/2026. It lists the method as cash proceeds from the exercise and includes prior 10b5-1 sales by Harold Bernstein.

Who is associated with the past 10b5-1 sales listed in the MAZE filing?

The past sales are attributed to Harold Bernstein, showing multiple 10b5-1 dispositions. Examples include 45,000 shares on 12/29/2025 and 25,156 shares on 01/07/2026

How will MAZE receive proceeds from the reported transaction?

The filing indicates the shares are being sold through exercise of stock options for cash on 03/10/2026. The document ties the method to cash proceeds; exact dollar proceeds from the exercise will appear in subsequent transaction reporting.

Does the Form 144 disclose the total cash value of the planned sale?

The notice specifies 74,853 shares to be sold by exercise on 03/10/2026 and lists prior sale dollar amounts. It does not present a single aggregated cash total for the planned exercise within the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:33 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002050172
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 Oyster Point Blvd Suite 300 South San Francisco CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	HAROLD BERNSTEIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	74853	3372876.18	48119444	03/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/10/2026	Exercise of Stock Options	Issuer			74853	03/10/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	02/02/2026	15000	690333.00
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	01/07/2026	25156	1011298.87
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	01/05/2026	412	16480.00
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	01/02/2026	4432	179187.53
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	12/29/2025	45000	1825353.00

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	03/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Harold Bernstein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)